1
|
Caldarella C, De Risi M, Massaccesi M, Miccichè F, Bussu F, Galli J, Rufini V, Leccisotti L. Role of 18F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: Current Evidence and Innovative Applications. Cancers (Basel) 2024; 16:1905. [PMID: 38791983 PMCID: PMC11119768 DOI: 10.3390/cancers16101905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2024] [Revised: 05/08/2024] [Accepted: 05/13/2024] [Indexed: 05/26/2024] Open
Abstract
This article provides an overview of the use of 18F-FDG PET/CT in various clinical scenarios of head-neck squamous cell carcinoma, ranging from initial staging to treatment-response assessment, and post-therapy follow-up, with a focus on the current evidence, debated issues, and innovative applications. Methodological aspects and the most frequent pitfalls in head-neck imaging interpretation are described. In the initial work-up, 18F-FDG PET/CT is recommended in patients with metastatic cervical lymphadenectomy and occult primary tumor; moreover, it is a well-established imaging tool for detecting cervical nodal involvement, distant metastases, and synchronous primary tumors. Various 18F-FDG pre-treatment parameters show prognostic value in terms of disease progression and overall survival. In this scenario, an emerging role is played by radiomics and machine learning. For radiation-treatment planning, 18F-FDG PET/CT provides an accurate delineation of target volumes and treatment adaptation. Due to its high negative predictive value, 18F-FDG PET/CT, performed at least 12 weeks after the completion of chemoradiotherapy, can prevent unnecessary neck dissections. In addition to radiomics and machine learning, emerging applications include PET/MRI, which combines the high soft-tissue contrast of MRI with the metabolic information of PET, and the use of PET radiopharmaceuticals other than 18F-FDG, which can answer specific clinical needs.
Collapse
Affiliation(s)
- Carmelo Caldarella
- Nuclear Medicine Unit, Department of Radiology and Oncologic Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; (C.C.); (M.D.R.); (L.L.)
| | - Marina De Risi
- Nuclear Medicine Unit, Department of Radiology and Oncologic Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; (C.C.); (M.D.R.); (L.L.)
| | - Mariangela Massaccesi
- Radiation Oncology Unit, Department of Radiology and Oncologic Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy;
| | - Francesco Miccichè
- Radiation Oncology Unit, Ospedale Isola Tiberina—Gemelli Isola, 00186 Rome, Italy;
| | - Francesco Bussu
- Otorhinolaryngology Operative Unit, Azienda Ospedaliero Universitaria Sassari, 07100 Sassari, Italy;
- Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy
| | - Jacopo Galli
- Otorhinolaryngology Unit, Department of Neurosciences, Sensory Organs and Thorax, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy;
- Section of Otolaryngology, Department of Head-Neck and Sensory Organs, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Vittoria Rufini
- Nuclear Medicine Unit, Department of Radiology and Oncologic Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; (C.C.); (M.D.R.); (L.L.)
- Section of Nuclear Medicine, Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Lucia Leccisotti
- Nuclear Medicine Unit, Department of Radiology and Oncologic Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; (C.C.); (M.D.R.); (L.L.)
- Section of Nuclear Medicine, Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| |
Collapse
|
2
|
Hu J, Yang Z, Gao J, Hu W, Yang J, Qiu X, Zhang Y, Ma G, Kong L, Lu JJ. Volumetric parameters derived from FLT-PET performed at completion of treatment predict efficacy of Carbon-ion Radiotherapy in patients with locally recurrent Nasopharyngeal Carcinoma. J Cancer 2020; 11:7073-7080. [PMID: 33123296 PMCID: PMC7591998 DOI: 10.7150/jca.46490] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 09/28/2020] [Indexed: 11/24/2022] Open
Abstract
The purpose of this study was to investigate the role of 3'-deoxy-3'-[18F]fluorothymidine (FLT)-PET for predicting the outcome of patients with locally recurrent nasopharyngeal carcinoma (LR-NPC) treated by carbon-ion radiotherapy (CIRT). Patients received FLT-PET/CT scan one-week prior to or after completion of CIRT were enrolled in the study. All patients were from prospective trials or treated using a standardized protocol. Time-dependent receiver operator characteristics (ROC) were used to determine the optimal cutoff values for FLT-PET parameters. Univariable and multivariable analyses of local progression-free survival (LPFS) were performed using Cox regression, to examine the prognostic value of FLT-PET parameters, including SUVmax, metabolic tumor volume (MTV) and total lesion thymidine (TLT). A total of 41 patients were enrolled. Elevated MTV and TLT were significantly associated with worse LPFS, in both univariable and multivariable analyses. ROC analysis revealed that both an MTV value higher than 8.6 and a TLT value higher than 14.9 were predictive of increased risk of developing local recurrence, the adjusted HRs were 5.59 (p=0.009) and 7.76 (p=0.002), respectively. In conclusion, FLT-PET was found to be a promising prognostic tool for LR-NPC patients and might play a role in the treatment guidance.
Collapse
Affiliation(s)
- Jiyi Hu
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China.,Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy
| | - Zhongyi Yang
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, China.,Department of Oncology, Shanghai Medical College, Fudan University, China.,Center for Biomedical Imaging, Fudan University, China.,Shanghai Engineering Research Center of Molecular Imaging Probes, China
| | - Jing Gao
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China.,Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy
| | - Weixu Hu
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China.,Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy
| | - Jing Yang
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China.,Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy
| | - Xianxin Qiu
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China.,Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy
| | - Yingjian Zhang
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, China.,Department of Oncology, Shanghai Medical College, Fudan University, China.,Center for Biomedical Imaging, Fudan University, China.,Shanghai Engineering Research Center of Molecular Imaging Probes, China
| | - Guang Ma
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, China
| | - Lin Kong
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 201321, China.,Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy
| | - Jiade J Lu
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China.,Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy
| |
Collapse
|
3
|
Abstract
Head and neck cancers are commonly encountered malignancies in the United States, of which the majority are attributed to squamous cell carcinoma. 18F-FDG-PET/CT has been well established in the evaluation, treatment planning, prognostic implications of these tumors and is routinely applied for the management of patients with these cancers. Many alternative investigational PET radiotracers have been extensively studied in the evaluation of these tumors. Although these radiotracers have not been able to replace 18F-FDG-PET/CT in routine clinical practice currently, they may provide important additional information about the biological mechanisms of these tumors, such as foci of tumor hypoxia as seen on hypoxia specific PET radiotracers such as 18F-Fluoromisonidazole (18F-FMISO), which could be useful in targeting radioresistant hypoxic tumor foci when treatment planning. There are multiple other hypoxia-specific PET radiotracers such as 18F-Fluoroazomycinarabinoside (FAZA), 18F-Flortanidazole (HX4), which have been evaluated similarly, of which 18F-Fluoromisonidazole (18F-FMISO) has been the most investigated. Other radiotracers frequently studied in the evaluation of these tumors include radiolabeled amino acid PET radiotracers, which show increased uptake in tumor cells with limited uptake in inflammatory tissue, which can be useful especially in differentiating postradiation inflammation from residual and/or recurrent disease. 18F-Fluorothymidine (FLT) is localized intracellularly by nucleoside transport and undergoes phosphorylation thereby being retained within tumor cells and can serve as an indicator of tumor proliferation. Decrease in radiotracer activity following treatment can be an early indicator of treatment response. This review aims at synthesizing the available literature on the most studied non-FDG-PET/CT in head and neck cancer.
Collapse
Affiliation(s)
- Charles Marcus
- Department of Radiology, West Virginia University, Morgantown, WV.
| | | |
Collapse
|
4
|
Ulrich EJ, Menda Y, Boles Ponto LL, Anderson CM, Smith BJ, Sunderland JJ, Graham MM, Buatti JM, Beichel RR. FLT PET Radiomics for Response Prediction to Chemoradiation Therapy in Head and Neck Squamous Cell Cancer. ACTA ACUST UNITED AC 2020; 5:161-169. [PMID: 30854454 PMCID: PMC6403029 DOI: 10.18383/j.tom.2018.00038] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Radiomics is an image analysis approach for extracting large amounts of quantitative information from medical images using a variety of computational methods. Our goal was to evaluate the utility of radiomic feature analysis from 18F-fluorothymidine positron emission tomography (FLT PET) obtained at baseline in prediction of treatment response in patients with head and neck cancer. Thirty patients with advanced-stage oropharyngeal or laryngeal cancer, treated with definitive chemoradiation therapy, underwent FLT PET imaging before treatment. In total, 377 radiomic features of FLT uptake and feature variants were extracted from volumes of interest; these features variants were defined by either the primary tumor or the total lesion burden, which consisted of the primary tumor and all FLT-avid nodes. Feature variants included normalized measurements of uptake, which were calculated by dividing lesion uptake values by the mean uptake value in the bone marrow. Feature reduction was performed using clustering to remove redundancy, leaving 172 representative features. Effects of these features on progression-free survival were modeled with Cox regression and P-values corrected for multiple comparisons. In total, 9 features were considered significant. Our results suggest that smaller, more homogenous lesions at baseline were associated with better prognosis. In addition, features extracted from total lesion burden had a higher concordance index than primary tumor features for 8 of the 9 significant features. Furthermore, total lesion burden features showed lower interobserver variability.
Collapse
Affiliation(s)
- Ethan J Ulrich
- Departments of Electrical and Computer Engineering.,Biomedical Engineering
| | | | | | | | | | | | | | | | - Reinhard R Beichel
- Departments of Electrical and Computer Engineering.,Internal Medicine, University of Iowa, Iowa City, IA
| |
Collapse
|
5
|
Prognostic value of 18F-FDG PET/CT functional parameters in patients with head and neck cancer. Nucl Med Commun 2019; 40:361-369. [DOI: 10.1097/mnm.0000000000000974] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Scarpelli M, Zahm C, Perlman S, McNeel DG, Jeraj R, Liu G. FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer 2019; 7:23. [PMID: 30700328 PMCID: PMC6354338 DOI: 10.1186/s40425-019-0516-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Accepted: 01/20/2019] [Indexed: 12/17/2022] Open
Abstract
Background Immunotherapy has demonstrated remarkable success in treating different cancers. Nonetheless, a large number of patients do not respond, many respond without immediate changes detectable with conventional imaging, and many have unusual immune-related adverse events that cannot be predicted in advance. In this exploratory study, we investigate how 3′-Deoxy-3’-18F-fluorothymidine (FLT) positron emission tomography (PET) measurements of tumor and immune cell proliferation might be utilized as biomarkers in immunotherapy. Methods Seventeen patients with metastatic castrate resistant prostate cancer were treated with combination pTVG-HP DNA vaccine and pembrolizumab. Patients underwent baseline and 12-week FLT PET/CT scans. FLT PET standardized uptake values (SUVs) were extracted from tumors, non-metastatic lymph nodes, spleen, bone marrow, pancreas, and thyroid to quantify cell proliferation in these tissues. Regional immune cell responses to pTVG-HP DNA vaccine were assessed by comparing FLT uptake changes in vaccine draining and non-draining lymph nodes. Cox proportional hazards regression was utilized to relate FLT uptake and other clinical markers (PSA and tumor size) to progression-free survival. Area under receiver operating characteristic (AUC) curves and concordance indices were used to assess the predictive capabilities of FLT uptake. Results Changes in FLT uptake in vaccine draining lymph nodes were significantly greater than changes in non-draining lymph nodes (P = 0.02), suggesting a regional immune response to vaccination. However, the changes in FLT uptake in lymph nodes were not significantly predictive of progression-free survival. Increases in tumor FLT uptake were significantly predictive of shorter progression-free survival (concordance index = 0.83, P < 0.01). Baseline FLT uptake in the thyroid was significantly predictive of whether or not a patient would subsequently experience a thyroid-related adverse event (AUC = 0.97, P < 0.01). Conclusions FLT PET uptake was significantly predictive of progression-free survival and the occurrence of adverse events relating to thyroid function. The results suggest FLT PET imaging has potential as a biomarker in immunotherapy, providing a marker of tumor and immune responses, and as a possible means of anticipating specific immune-related adverse events. Trial registration NCT02499835. Electronic supplementary material The online version of this article (10.1186/s40425-019-0516-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Matthew Scarpelli
- Department of Medical Physics, University of Wisconsin, 1111 Highland Ave, Madison, WI, 53792, USA
| | - Christopher Zahm
- University of Wisconsin Carbone Cancer Center, 1111 Highland Ave, Madison, WI, 53792, USA
| | - Scott Perlman
- University of Wisconsin Carbone Cancer Center, 1111 Highland Ave, Madison, WI, 53792, USA.,Department of Radiology, Section of Nuclear Medicine, University of Wisconsin, 600 Highland Avenue, Madison, WI, 53792, USA
| | - Douglas G McNeel
- University of Wisconsin Carbone Cancer Center, 1111 Highland Ave, Madison, WI, 53792, USA.,Department of Medicine, Division of Hematology/Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI, 53792, USA
| | - Robert Jeraj
- Department of Medical Physics, University of Wisconsin, 1111 Highland Ave, Madison, WI, 53792, USA.,University of Wisconsin Carbone Cancer Center, 1111 Highland Ave, Madison, WI, 53792, USA.,Department of Radiology, Section of Nuclear Medicine, University of Wisconsin, 600 Highland Avenue, Madison, WI, 53792, USA
| | - Glenn Liu
- University of Wisconsin Carbone Cancer Center, 1111 Highland Ave, Madison, WI, 53792, USA. .,Department of Medicine, Division of Hematology/Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI, 53792, USA.
| |
Collapse
|
7
|
Gage KL, Thomas K, Jeong D, Stallworth DG, Arrington JA. Multimodal Imaging of Head and Neck Squamous Cell Carcinoma. Cancer Control 2018; 24:172-179. [DOI: 10.1177/107327481702400209] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Affiliation(s)
- Kenneth L. Gage
- Diagnostic Imaging and Interventional Radiology Program,
University of South Florida College of Medicine, Tampa, Florida
| | - Kerry Thomas
- Diagnostic Imaging and Interventional Radiology Program,
University of South Florida College of Medicine, Tampa, Florida
| | - Daniel Jeong
- Diagnostic Imaging and Interventional Radiology Program,
University of South Florida College of Medicine, Tampa, Florida
| | - Dexter G. Stallworth
- Diagnostic Imaging and Interventional Radiology Program,
University of South Florida College of Medicine, Tampa, Florida
| | - John A. Arrington
- H. Lee Moffitt Cancer Center & Research Institute, and the Departments of Oncologic Sciences, University of South Florida College of Medicine, Tampa, Florida
- Radiology, University of South Florida College of Medicine,
Tampa, Florida
| |
Collapse
|
8
|
Im HJ, Zhang Y, Wu H, Wu J, Daw NC, Navid F, Shulkin BL, Cho SY. Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. Radiology 2018; 287:303-312. [PMID: 29357275 DOI: 10.1148/radiol.2017162758] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Purpose To preliminarily assess the potential prognostic value of various fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) parameters before, during, and after neoadjuvant chemotherapy (NCT). Materials and Methods Thirty-four patients with osteosarcoma were enrolled prospectively from 2008 to 2012 and underwent FDG PET/computed tomography (CT) imaging before (baseline scan), during (interim scan) and after NCT (posttherapy scan). The study was approved by the institutional review board and informed consent was received from patients. Maximum and peak standardized uptake value (SUVmax and SUVpeak), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. Predictive value of FDG PET parameters for event-free survival (EFS) and overall survival (OS) were evaluated. Multivariable Cox regression analysis for EFS and OS was performed by using histologic response and initial presence of metastasis as covariates. Results At baseline scan, SUVpeak, MTV, and TLG were predictive of EFS (P = .006-.03) and OS (P = .001-.03) but not associated with histologic response. At interim and posttherapy scan, SUVmax, SUVpeak, MTV, and TLG were associated with histologic response (P = .0002-.04) and predictive of EFS (P = .004-.02) and OS (P = .001-.03). Multivariable Cox regression analysis revealed that the FDG PET parameters either at baseline, interim, or posttherapy were independently predictive of EFS and OS. In particular, baseline MTV was an independent predictor of EFS (hazard ratio, 5.0 [95% confidence interval {CI}: 1.5, 16.8]) and OS (hazard ratio, 29.4 [95% CI: 2.2, 392.2]). Conclusion SUVpeak, MTV, and TLG either at baseline, interim, or posttherapy were predictive of EFS and OS and may be useful prognostic biomarkers for osteosarcoma. © RSNA, 2018 Online supplemental material is available for this article.
Collapse
Affiliation(s)
- Hyung-Jun Im
- From the Department of Radiology, Nuclear Medicine/PET Section, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705 (H.J.I., Y.Z., S.Y.C.); Departments of Biostatistics (H.W., J.W.) and Diagnostic Imaging (B.L.S.), St. Jude Children's Research Hospital, Memphis, Tenn; Department of Pediatrics, MD Anderson Cancer Center, Houston, Tex (N.C.D.); Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, Calif (F.N.); Keck School of Medicine, University of Southern California, Los Angeles, Calif (F.N.); and University of Wisconsin Carbone Cancer Center, Madison, Wis (S.Y.C.)
| | - Yi Zhang
- From the Department of Radiology, Nuclear Medicine/PET Section, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705 (H.J.I., Y.Z., S.Y.C.); Departments of Biostatistics (H.W., J.W.) and Diagnostic Imaging (B.L.S.), St. Jude Children's Research Hospital, Memphis, Tenn; Department of Pediatrics, MD Anderson Cancer Center, Houston, Tex (N.C.D.); Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, Calif (F.N.); Keck School of Medicine, University of Southern California, Los Angeles, Calif (F.N.); and University of Wisconsin Carbone Cancer Center, Madison, Wis (S.Y.C.)
| | - Huiyun Wu
- From the Department of Radiology, Nuclear Medicine/PET Section, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705 (H.J.I., Y.Z., S.Y.C.); Departments of Biostatistics (H.W., J.W.) and Diagnostic Imaging (B.L.S.), St. Jude Children's Research Hospital, Memphis, Tenn; Department of Pediatrics, MD Anderson Cancer Center, Houston, Tex (N.C.D.); Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, Calif (F.N.); Keck School of Medicine, University of Southern California, Los Angeles, Calif (F.N.); and University of Wisconsin Carbone Cancer Center, Madison, Wis (S.Y.C.)
| | - Jianrong Wu
- From the Department of Radiology, Nuclear Medicine/PET Section, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705 (H.J.I., Y.Z., S.Y.C.); Departments of Biostatistics (H.W., J.W.) and Diagnostic Imaging (B.L.S.), St. Jude Children's Research Hospital, Memphis, Tenn; Department of Pediatrics, MD Anderson Cancer Center, Houston, Tex (N.C.D.); Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, Calif (F.N.); Keck School of Medicine, University of Southern California, Los Angeles, Calif (F.N.); and University of Wisconsin Carbone Cancer Center, Madison, Wis (S.Y.C.)
| | - Najat C Daw
- From the Department of Radiology, Nuclear Medicine/PET Section, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705 (H.J.I., Y.Z., S.Y.C.); Departments of Biostatistics (H.W., J.W.) and Diagnostic Imaging (B.L.S.), St. Jude Children's Research Hospital, Memphis, Tenn; Department of Pediatrics, MD Anderson Cancer Center, Houston, Tex (N.C.D.); Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, Calif (F.N.); Keck School of Medicine, University of Southern California, Los Angeles, Calif (F.N.); and University of Wisconsin Carbone Cancer Center, Madison, Wis (S.Y.C.)
| | - Fariba Navid
- From the Department of Radiology, Nuclear Medicine/PET Section, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705 (H.J.I., Y.Z., S.Y.C.); Departments of Biostatistics (H.W., J.W.) and Diagnostic Imaging (B.L.S.), St. Jude Children's Research Hospital, Memphis, Tenn; Department of Pediatrics, MD Anderson Cancer Center, Houston, Tex (N.C.D.); Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, Calif (F.N.); Keck School of Medicine, University of Southern California, Los Angeles, Calif (F.N.); and University of Wisconsin Carbone Cancer Center, Madison, Wis (S.Y.C.)
| | - Barry L Shulkin
- From the Department of Radiology, Nuclear Medicine/PET Section, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705 (H.J.I., Y.Z., S.Y.C.); Departments of Biostatistics (H.W., J.W.) and Diagnostic Imaging (B.L.S.), St. Jude Children's Research Hospital, Memphis, Tenn; Department of Pediatrics, MD Anderson Cancer Center, Houston, Tex (N.C.D.); Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, Calif (F.N.); Keck School of Medicine, University of Southern California, Los Angeles, Calif (F.N.); and University of Wisconsin Carbone Cancer Center, Madison, Wis (S.Y.C.)
| | - Steve Y Cho
- From the Department of Radiology, Nuclear Medicine/PET Section, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705 (H.J.I., Y.Z., S.Y.C.); Departments of Biostatistics (H.W., J.W.) and Diagnostic Imaging (B.L.S.), St. Jude Children's Research Hospital, Memphis, Tenn; Department of Pediatrics, MD Anderson Cancer Center, Houston, Tex (N.C.D.); Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, Calif (F.N.); Keck School of Medicine, University of Southern California, Los Angeles, Calif (F.N.); and University of Wisconsin Carbone Cancer Center, Madison, Wis (S.Y.C.)
| |
Collapse
|
9
|
Quartuccio N, Caobelli F, Di Mauro F, Cammaroto G. Non-18F-FDG PET/CT in the management of patients affected by HNC: state-of-the-art. Nucl Med Commun 2016; 37:891-8. [PMID: 27139114 DOI: 10.1097/mnm.0000000000000530] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PET/computed tomography with F-fluorodeoxyglucose is considered a powerful molecular imaging technique that can provide useful information in the management of patients affected by head and neck cancer. However, misleading findings have been reported because of nonspecific uptake caused by peritumoural inflammation and physiologic changes in nonmalignant tissues in the head and neck region. More specific β-emitting tracers have been introduced that can track other pathological processes. We aimed to review the existing literature performing the search until June 2015 on non-F-fluorodeoxyglucose PET tracers in head and neck cancer to highlight their role in clinical practice.
Collapse
Affiliation(s)
- Natale Quartuccio
- aWolfson Molecular Imaging Centre, University of Manchester, Manchester, UK bDepartment of Nuclear Medicine, Hannover Medical School, Hanover, Germany cDepartment of Nuclear Medicine, Universitätsspital Basel, Basel, Switzerland dNuclear Medicine Unit, Department of Biomedical Sciences and Morphologic and Functional Images eDepartment of Otorhinolaryngology, University of Messina, Messina fYoung Executive Committee of the Italian Association of Nuclear Medicine (AIMN), Milan, Italy
| | | | | | | | | |
Collapse
|
10
|
Min M, Lin P, Liney G, Lee M, Forstner D, Fowler A, Holloway L. A review of the predictive role of functional imaging in patients with mucosal primary head and neck cancer treated with radiation therapy. J Med Imaging Radiat Oncol 2016; 61:99-123. [DOI: 10.1111/1754-9485.12496] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2015] [Accepted: 06/11/2016] [Indexed: 12/14/2022]
Affiliation(s)
- Myo Min
- Cancer Therapy Centre; Liverpool Hospital; Liverpool New South Wales Australia
- South Western Clinical School; University of New South Wales; Sydney New South Wales Australia
- Ingham Institute of Applied Medical Research; Liverpool New South Wales Australia
| | - Peter Lin
- South Western Clinical School; University of New South Wales; Sydney New South Wales Australia
- Department of Nuclear Medicine and Positron Emission Tomography; Liverpool Hospital; Liverpool New South Wales Australia
- University of Western Sydney; Sydney New South Wales Australia
| | - Gary Liney
- Cancer Therapy Centre; Liverpool Hospital; Liverpool New South Wales Australia
- South Western Clinical School; University of New South Wales; Sydney New South Wales Australia
- Ingham Institute of Applied Medical Research; Liverpool New South Wales Australia
- Centre for Medical Radiation Physics; University of Wollongong; Wollongong New South Wales Australia
| | - Mark Lee
- Cancer Therapy Centre; Liverpool Hospital; Liverpool New South Wales Australia
- South Western Clinical School; University of New South Wales; Sydney New South Wales Australia
| | - Dion Forstner
- Cancer Therapy Centre; Liverpool Hospital; Liverpool New South Wales Australia
- South Western Clinical School; University of New South Wales; Sydney New South Wales Australia
- Ingham Institute of Applied Medical Research; Liverpool New South Wales Australia
| | - Allan Fowler
- Cancer Therapy Centre; Liverpool Hospital; Liverpool New South Wales Australia
| | - Lois Holloway
- Cancer Therapy Centre; Liverpool Hospital; Liverpool New South Wales Australia
- South Western Clinical School; University of New South Wales; Sydney New South Wales Australia
- Ingham Institute of Applied Medical Research; Liverpool New South Wales Australia
- Centre for Medical Radiation Physics; University of Wollongong; Wollongong New South Wales Australia
- Institute of Medical Physics; School of Physics; University of Sydney; Sydney New South Wales Australia
| |
Collapse
|
11
|
A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer 2016; 55:81-97. [PMID: 26820682 DOI: 10.1016/j.ejca.2015.11.018] [Citation(s) in RCA: 80] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Accepted: 11/15/2015] [Indexed: 12/19/2022]
Abstract
Imaging biomarkers have a potential to depict the hallmarks of cancers that characterise cancer cells as compared to normal cells. One pertinent example is 3'-deoxy-3'-(18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET), which allows non-invasive in vivo assessment of tumour proliferation. Most importantly, [(18)F]FLT does not seem to be accumulating in inflammatory processes, as seen in [(18)F]-fludeoxyglucose, the most commonly used PET tracer for assessment of cell metabolism. [(18)F]FLT could therefore provide additional information about the tumour biology before, during and after treatment. This systematic review focuses on the use of [(18)F]FLT-PET tumour uptake values as a measure of tumour response to therapeutic interventions. The clinical studies which evaluated the role of [(18)F]FLT-PET as a measure of tumour response to treatment are summarised and the evidence linking [(18)F]FLT-PET tumour uptake values with clinical outcome is evaluated.
Collapse
|
12
|
Clark J, Jeffery CC, Zhang H, Cooper T, O'Connell DA, Harris J, Seikaly H, Biron VL. Correlation of PET-CT nodal SUVmax with p16 positivity in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg 2015; 44:37. [PMID: 26374294 PMCID: PMC4570692 DOI: 10.1186/s40463-015-0091-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Accepted: 09/02/2015] [Indexed: 11/10/2022] Open
Abstract
Background The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) has been rising in recent years. Given the clinical impact of HPV/p16 positivity in OPSCC, identifying surrogate markers of this disease early in the diagnostic work-up of these patients could improve patient care. Methods Demographic, pathologic, staging and PET-CT data from patients diagnosed with OPSCC from 2009–2014 were obtained from a prospectively collected provincial cancer registry. Tumor HPV/p16 status was correlated to the maximum standard uptake value (SUVmax) of the primary tumor and cervical nodes. Comparisons of means and multinomial regression models were used to determine associations between p16 status and SUVmax. A diagnostic odds ratio was calculated using a cut off value for predicting HPV/p16 positivity based on nodal SUVmax. Results PET-CT and HPV/p16 data was obtained for 65 patients treated surgically for OPSCC. Significantly higher nodal SUVmax was associated with HPV/p16 positive nodes (SUVmax 10.8 vs 7.9). No significant differences were seen between HPV/p16 positive vs negative primary tumor SUVmax (10.3 vs 13.7). In combination with other clinical parameters, higher nodal SUVmax was highly correlated with HPV/p16 positivity. Conclusion Elevated nodal SUVmax is a significant predictor of HPV/p16 positive disease.
Collapse
Affiliation(s)
- Jessica Clark
- Faculty of Medicine and Dentistry, Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, Alberta, Canada.
| | - Caroline C Jeffery
- Faculty of Medicine and Dentistry, Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, Alberta, Canada.
| | - Han Zhang
- Faculty of Medicine and Dentistry, Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, Alberta, Canada.
| | - Tim Cooper
- Faculty of Medicine and Dentistry, Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, Alberta, Canada.
| | - Daniel A O'Connell
- Faculty of Medicine and Dentistry, Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, Alberta, Canada. dan.o'
| | - Jeffrey Harris
- Faculty of Medicine and Dentistry, Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, Alberta, Canada.
| | - Hadi Seikaly
- Faculty of Medicine and Dentistry, Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, Alberta, Canada.
| | - Vincent L Biron
- Faculty of Medicine and Dentistry, Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, Alberta, Canada. .,University of Alberta, Otolaryngology-Head and Neck Surgery, 1E4, Walter Mackenzie Centre, University of Alberta Hospital, 8440-112St, Edmonton, Alberta, T6G 2B7, Canada.
| |
Collapse
|